BACKGROUND: Antibiotic use may be associated with higher breast cancer risk and breast cancer mortality, but no study has evaluated the relation between antibiotic use and second breast cancer events (SBCE). METHODS: We conducted a retrospective cohort study among women ≥18 years, diagnosed with incident stage I/II breast cancer during 1990-2008. Antibiotic use and covariates were obtained from health plan administrative databases and medical record review. Frequent antibiotic use was defined as ≥4 antibiotic dispensings in any moving 12-month period after diagnosis. Our outcome was SBCE defined as recurrence or second primary breast cancer. We used multivariable Cox proportional hazards models to estimate HR and 95% confidence intervals (CI), accounting for competing risks. RESULTS: A total of 4,216 women were followed for a median of 6.7 years. Forty percent were frequent antibiotic users and 558 (13%) had an SBCE. Results are suggestive of a modest increased risk of SBCE (HR, 1.15; 95% CI, 0.88-1.50) among frequent antibiotic users compared with nonusers. Any potential increased risk was not supported when we evaluated recent use and past use. We observed no dose-response trends for SBCE with increasing duration of antibiotic use nor did we find evidence for altered SBCE risk in the antibiotic classes studied. CONCLUSIONS: Frequent antibiotic use may be associated with modestly elevated risk of SBCEs, but the association was not significant. IMPACT: Additional investigation by antibiotic class and underlying indication are important next steps given the high prevalence of frequent antibiotic use and growing number of breast cancer survivors.
BACKGROUND: Antibiotic use may be associated with higher breast cancer risk and breast cancer mortality, but no study has evaluated the relation between antibiotic use and second breast cancer events (SBCE). METHODS: We conducted a retrospective cohort study among women ≥18 years, diagnosed with incident stage I/II breast cancer during 1990-2008. Antibiotic use and covariates were obtained from health plan administrative databases and medical record review. Frequent antibiotic use was defined as ≥4 antibiotic dispensings in any moving 12-month period after diagnosis. Our outcome was SBCE defined as recurrence or second primary breast cancer. We used multivariable Cox proportional hazards models to estimate HR and 95% confidence intervals (CI), accounting for competing risks. RESULTS: A total of 4,216 women were followed for a median of 6.7 years. Forty percent were frequent antibiotic users and 558 (13%) had an SBCE. Results are suggestive of a modest increased risk of SBCE (HR, 1.15; 95% CI, 0.88-1.50) among frequent antibiotic users compared with nonusers. Any potential increased risk was not supported when we evaluated recent use and past use. We observed no dose-response trends for SBCE with increasing duration of antibiotic use nor did we find evidence for altered SBCE risk in the antibiotic classes studied. CONCLUSIONS: Frequent antibiotic use may be associated with modestly elevated risk of SBCEs, but the association was not significant. IMPACT: Additional investigation by antibiotic class and underlying indication are important next steps given the high prevalence of frequent antibiotic use and growing number of breast cancer survivors.
Authors: Denise M Boudreau; Mark P Doescher; J Elizabeth Jackson; Paul A Fishman; Barry G Saver Journal: Ann Pharmacother Date: 2004-05-18 Impact factor: 3.154
Authors: K D Setchell; A M Lawson; S P Borriello; R Harkness; H Gordon; D M Morgan; D N Kirk; H Adlercreatz; L C Anderson; M Axelson Journal: Lancet Date: 1981-07-04 Impact factor: 79.321
Authors: Christine M Velicer; Susan R Heckbert; Johanna W Lampe; John D Potter; Carol A Robertson; Stephen H Taplin Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Christine M Velicer; Johanna W Lampe; Susan R Heckbert; John D Potter; Stephen H Taplin Journal: Cancer Causes Control Date: 2003-10 Impact factor: 2.506
Authors: Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau Journal: Cancer Causes Control Date: 2015-10-30 Impact factor: 2.506
Authors: Gregory S Calip; Onchee Yu; Denise M Boudreau; Huibo Shao; Ruth Oratz; Stephen B Richardson; Heather T Gold Journal: Cancer Causes Control Date: 2019-04-04 Impact factor: 2.506
Authors: Heidi S Wirtz; Denise M Boudreau; Julie R Gralow; William E Barlow; Shelly Gray; Erin J A Bowles; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-01-10 Impact factor: 4.872
Authors: Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau Journal: Am J Epidemiol Date: 2017-04-15 Impact factor: 4.897
Authors: Gregory S Calip; Rebecca A Hubbard; Andy Stergachis; Kathleen E Malone; Julie R Gralow; Denise M Boudreau Journal: Pharmacoepidemiol Drug Saf Date: 2014-06-13 Impact factor: 2.890
Authors: Elizabeth T Loggers; Hongyuan Gao; Laura S Gold; Larry Kessler; Ruth Etzioni; Diana Sm Buist Journal: J Comp Eff Res Date: 2015-05-11 Impact factor: 1.744
Authors: David S Carrell; Scott Halgrim; Diem-Thy Tran; Diana S M Buist; Jessica Chubak; Wendy W Chapman; Guergana Savova Journal: Am J Epidemiol Date: 2014-01-30 Impact factor: 4.897
Authors: Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-02-21 Impact factor: 4.872
Authors: Gregory S Calip; Kathleen E Malone; Julie R Gralow; Andy Stergachis; Rebecca A Hubbard; Denise M Boudreau Journal: Breast Cancer Res Treat Date: 2014-10-10 Impact factor: 4.872